Lifecore Biomedical, Inc. (NASDAQ:LFCR) Major Shareholder Aron R. English Sells 24,543 Shares

Lifecore Biomedical, Inc. (NASDAQ:LFCR) major shareholder Aron R. English sold 24,543 shares of the stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $7.08, for a total transaction of $173,764.44. Following the transaction, the insider now owns 1,730,618 shares in the company, valued at $12,252,775.44. The trade was a 1.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Lifecore Biomedical Trading Up 0.6 %

NASDAQ LFCR opened at $7.00 on Thursday. The stock has a 50-day moving average of $6.36 and a 200-day moving average of $6.47. The company has a current ratio of 2.32, a quick ratio of 1.21 and a debt-to-equity ratio of 9.21. Lifecore Biomedical, Inc. has a 1-year low of $3.68 and a 1-year high of $7.99. The firm has a market cap of $258.99 million, a PE ratio of -12.49 and a beta of 0.65.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings results on Thursday, April 3rd. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $35.15 million during the quarter, compared to analysts’ expectations of $33.23 million. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. As a group, sell-side analysts forecast that Lifecore Biomedical, Inc. will post -0.91 EPS for the current year.

Institutional Trading of Lifecore Biomedical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Hurley Capital LLC bought a new stake in shares of Lifecore Biomedical in the 1st quarter worth approximately $35,000. Bank of New York Mellon Corp grew its holdings in shares of Lifecore Biomedical by 3.8% during the first quarter. Bank of New York Mellon Corp now owns 83,663 shares of the company’s stock valued at $589,000 after buying an additional 3,091 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Lifecore Biomedical by 1,839.7% during the first quarter. GAMMA Investing LLC now owns 3,569 shares of the company’s stock valued at $25,000 after acquiring an additional 3,385 shares in the last quarter. Legion Partners Asset Management LLC raised its holdings in Lifecore Biomedical by 49.3% in the 4th quarter. Legion Partners Asset Management LLC now owns 4,431,823 shares of the company’s stock worth $32,928,000 after acquiring an additional 1,463,414 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its position in Lifecore Biomedical by 2.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 78,800 shares of the company’s stock valued at $585,000 after acquiring an additional 1,900 shares in the last quarter. 83.36% of the stock is currently owned by hedge funds and other institutional investors.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.